This site is intended for health professionals only

Sunday 21 July 2019
Share |

Topic: cancer

December 6, 2018
Delays in taking new cancer drugs through clinical trials and getting them approved for use mean NHS patients are waiting longer to access them, a report by the Institute of Cancer Research (ICR) finds.

NHS patients are waiting longer for new cancer drugs because of delays in taking them through clinical trials and getting them approved for use, a new report has revealed.

The average time from when a cancer drug is patented to approval by NICE increased from 12.7 years between 2000-08 to 14.1 years between 2009-16, The Institute of Cancer Research, London (ICR) found.

November 30, 2018
Cancer patients in England have a poorer survival rate than patients in other European countries, according to the Health Foundation.

Cancer patients in England have a poorer survival rate than patients in other European countries, according to the Health Foundation.
 
A report by the charity looked at the progress made since the NHS Cancer Plan in 2000, which aimed to see five-year survival rates for cancer in England compare with the best in Europe by 2010.
 
Delays in diagnosis and treatment
 

November 29, 2018
CAR-T treatment involves collecting and using a patient’s own immune cells to fight the cancer over a number of weeks.

Children with cancer at Great Ormond Street Hospital in London are this week starting a new therapy treatment tailored to target patients’ specific cancer cells.
 
The CAR-T treatment involves collecting and using a patient’s own immune cells to fight the cancer over a number of weeks. 
 
Royal Manchester Children’s Hospital is also offering the immunotherapy treatment, and Newcastle upon Tyne Hospitals NHS Foundation Trust will join next month.
 

November 13, 2018
Excess fat causes the body’s cancer-fighting “natural killer cells” to fail, explaining the link between obesity and cancer, researchers have said.

Excess fat causes the body’s cancer-fighting “natural killer cells” to fail, explaining the link between obesity and cancer, researchers have said.
 
Researchers at Trinity College Dublin worked with natural killer cells from humans – as well as using mice – found that when these cells become clogged with fat, they are prevented from killing tumour cells although they can still recognise them.
 

October 26, 2018
The study, by Erasmus University Medical Centre (EUMC), looked at data from 20 European countries, including the United Kingdom, France and the Netherlands.

The number of patients diagnosed with bowel cancer in Europe has been steadily increasing over the past 25 years, according to new research.
 
Between 2008 and 2016, diagnosis rates for bowel cancer, which is also known as colorectal cancer, increased by 6% every year in adults aged 20 to 39 years old.
 
For colon cancer, rates increased by 1.5% a year between 1990 and 2008, and an even greater 7.4% annually between 2008 and 2016, whereas rectal cancer was slightly slower at 1.8% per year from 1990 to 2016.
 

October 17, 2018

Eli Lilly and Company announced today that the European Commission has granted marketing authorisation (MA) for Verzenios® (abemaciclib) for the treatment of women with hormone receptor-positive (HR+), epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer, in combination with an aromatase inhibitor (AI) or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.1
 

October 3, 2018

The Nobel prize for physiology or medicine has gone to two scientists who have discovered how to fight cancer using the body’s immune system.
 
Professor James Allison from the University of Texas and Professor Tasuku Honjo from Kyoto University were awarded the prize for their ‘discovery of cancer therapy by inhibition of negative immune regulation’.
 
Their research has led to treatments for advanced skin cancer, which experts have said has proved to be ‘strikingly effective’.
 

August 30, 2018
Vyxeos is an advanced liposomal formulation that delivers a synergistic molar ratio of daunorubicin and cytarabine

The European Commission has approved Vyxeos 44 mg/100mg powder for concentrate for solution for infusion for the treatment of adults with newly-diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes, manufacturer Jazz Pharmaceuticals has announced.

 

Vyxeos is an advanced liposomal formulation that delivers a synergistic molar ratio of daunorubicin and cytarabine, Jazz Pharmaceuticals said.

 

August 30, 2018

Novartis UK Oncology statement on Novartis receiving European Commission approval of its CAR-T cell therapy, Kymriah® (tisagenlecleucel)
 
"Today’s (27 August) approval by the European Commission of Kymriah® (tisagenlecleucel), the only CAR-T therapy licensed in two different types of blood cancers, moves us one step closer to providing this revolutionary therapy to appropriate patients in the UK. 
 
 

August 6, 2018
New patient groups with cancer-associated venous thromboembolism (VTE) could benefit from taking once-daily oral LIXIANA (edoxaban), a recent analysis has said.

New patient groups with cancer-associated venous thromboembolism (VTE) could benefit from taking once-daily oral LIXIANA (edoxaban), a recent analysis has said.
 
Manufacturer Daiichi Sankyo announced today (6 July) it had published a new analysis on the clinical presentation, course and outcome of bleeding events in Thrombosis and Haemostasis, and the associated tumour types from the Hokusai-VTE cancer study.
 

July 2, 2018
The CHMP has given a positive opinion recommending Novartis’s Kymriah (tisagenlecleucel) to treat two aggressive blood cancers.

The Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion recommending Novartis’s Kymriah (tisagenlecleucel) to treat two aggressive blood cancers.
 
The CHMP, which is part of the European Medicines Agency (EMA), gave a positive opinion on using tisagenlecleucel to treat B-cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post-stem cell transplant or in second or later relapse in patients up to 25 years of age.
 

June 21, 2018
Targeted therapy to block a protein that suppresses T cell activity could improve cancer treatment with immune checkpoint inhibitors

A targeted therapy to block a protein that suppresses T cell activity could improve cancer treatment with immune checkpoint inhibitors, researchers have found.
 
EZH2 is elevated in immune T cells in patients after treatment with ipilimumab, a team at the University of Texas MD Anderson Cancer Center showed. The drug unleashes an immune response by blocking the activity of CTLA-4 on T cells – white blood cells that serve as the ‘targeted warriors’ of the adaptive immune system.
 

May 11, 2018
NHS failure to send invitations may have resulted in women having their lives shortened, according to estimates

Nearly half a million women in England have missed out on a routine breast screening appointment due to an NHS failure to send invitations. 

Up to 270 women may have had their lives shortened as a result, according to estimates. A computer error has been blamed for the missed invitations.

April 26, 2018
Personal cancer stories focus more on younger people despite majority of all cancers in the UK being diagnosed in over 60s

Older adults are underrepresented in the media’s coverage of cancer and cancer experiences, researchers have found. This is despite over three quarters of all cancers in the UK being diagnosed in those aged over 60.

According to research led by the University of Glasgow and funded by Cancer Research UK, articles featuring personal cancer stories more frequently focus on younger people.

April 9, 2018
New centres being set up across the country mark a "step change" in cancer care NHS England said

‘One stop shops’ aimed at speeding up cancer diagnosis are being rolled out across the country, NHS England has announced (3 April).

Rapid diagnostic and assessment centres are being piloted in ten areas as part of NHS England’s drive to catch cancer early and help save lives.

March 26, 2018
Positive opinion for ABP 980 is supported by Phase III data in patients with HER2-postive early breast cancer

Amgen and Allergan have announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the marketing authorisation of ABP 980, a biosimilar to Herceptin® (trastuzumab).

January 19, 2018
Marketing authorisation based on global development program showing MVASI is highly similar to Avastin® (bevacizumab)

Amgen and Allergan plc have that the European Commission (EC) has granted marketing authorisation for MVASI® (biosimilar bevacizumab).

November 27, 2017
Survey highlights need for improved education and standardised referral pathways for oncofertility

Results of a new survey highlight the need for improved education and standardised guidance for oncologists initiating cancer treatment in women who may want to safeguard their fertility.1

November 16, 2017
ABP 215 is being developed as a biosimilar to bevacizumab

Amgen and Allergan have announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the Marketing Authorisation of ABP 215, a biosimilar to Avastin® (bevacizumab).

September 21, 2017
Cancer patients received less recommended drugs and interventions for myocardial infarction and were more likely to die

Treatment of heart attack patients depends on their history of cancer, according to research published in the European Heart Journal: Acute Cardiovascular Care.1

July 7, 2016

 The National Institute for Health and Care Excellence (NICE) has issued evidence-based guidelines recommending the use of a minimally-invasive blood test to test for and monitor advanced liver fibrosis in people diagnosed with non-alcoholic fatty liver disease (NAFLD).

February 4, 2016
Today is World Cancer Day 2016 and COCIR is taking this opportunity to raise awareness about the new and efficient clinical processes that medical technologies are enabling for the benefit of citizens and cancer patients across the globe in the collective fight against cancer.

Today is World Cancer Day 2016 and COCIR is taking this opportunity to raise awareness about the new and efficient clinical processes that medical technologies are enabling for the benefit of citizens and cancer patients across the globe in the collective fight against cancer.
 

June 25, 2015
Integration of all necessary process and production steps for manufacturing individualised vaccines against cancer (IVAC®)
September 24, 2009
Collaboration to investigate expansion of ThermoDox indications in pancreatic cancer and bone metastases

Royal Philips Electronics and Celsion Corporation have announced that their joint research program to evaluate ThermoDox, Celsion's heat-activated liposomal drug, in combination with magnetic resonance guided high intensity focused ultrasound (MR-HIFU) as a combination therapy to non-invasively treat difficult cancers has successfully completed the feasibility stage.

The program has now moved into pre-clinical development and will focus on the combined use of ThermoDox and Philips' MR-HIFU system for the treatment of pancreatic cancer and cancer metastases in bone.